FDA Approves Inluriyo (imlunestrant) in Combination with Verzenio (abemaciclib) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Sep 22, 2026 - 22:00
 0  0
INDIANAPOLIS, Sept. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antagonist, in...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0